What are 5-HT2C receptor agonist drugs?

5-HT2C receptor agonist drugs are pharmacologic agents that share a common mechanism (typically targeting 5-HT2C receptor). 1 are currently marketed, with 2 more in clinical development.

What are the marketed 5-HT2C receptor agonist drugs?

Marketed 5-HT2C receptor agonist drugs include Lorcaserin HCl.

5-HT2C receptor agonist

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 marketed 2 in Phase 3

This page covers all 5-HT2C receptor agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting 5-HT2C receptor.

Targets

5-HT2C receptor

Marketed (1)

Lorcaserin HCl · Beth Israel Deaconess Medical Center · Obesity/Weight Management
Lorcaserin is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.

Phase 3 pipeline (2)

JNT-517 Tablet · Otsuka Pharmaceutical Development & Commercialization, Inc. · Obesity / Metabolic Disease
JNT-517 is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.
OPC-1085EL · Otsuka Beijing Research Institute · Obesity/Metabolic Disease
OPC-1085EL is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.

Patent intelligence

5 ht2c receptor agonist patent landscape — aggregated cliff calendar, attackable patents, originator estates